Ross Martin

2.1k total citations
56 papers, 1.3k citations indexed

About

Ross Martin is a scholar working on Infectious Diseases, Epidemiology and Hepatology. According to data from OpenAlex, Ross Martin has authored 56 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Infectious Diseases, 30 papers in Epidemiology and 30 papers in Hepatology. Recurrent topics in Ross Martin's work include Hepatitis C virus research (30 papers), Hepatitis B Virus Studies (26 papers) and HIV/AIDS drug development and treatment (25 papers). Ross Martin is often cited by papers focused on Hepatitis C virus research (30 papers), Hepatitis B Virus Studies (26 papers) and HIV/AIDS drug development and treatment (25 papers). Ross Martin collaborates with scholars based in United States, France and Canada. Ross Martin's co-authors include Hongmei Mo, Evguenia S. Svarovskaia, Diana M. Brainard, Michael D. Miller, Hadas Dvory‐Sobol, Charlotte Hedskog, Brian Doehle, Silvia Chang, John G. McHutchison and Eric Lawitz and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Gastroenterology and Clinical Infectious Diseases.

In The Last Decade

Ross Martin

54 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ross Martin United States	21	907	860	713	223	122	56	1.3k
Eliot Godofsky United States	19	762 0.8×	765 0.9×	508 0.7×	283 1.3×	118 1.0×	27	1.2k
Giulia Morsica Italy	18	1.1k 1.2×	1.0k 1.2×	241 0.3×	86 0.4×	69 0.6×	73	1.3k
Caroline Scholtès France	20	915 1.0×	867 1.0×	308 0.4×	72 0.3×	147 1.2×	46	1.2k
Pascale Trimoulet France	16	631 0.7×	606 0.7×	228 0.3×	52 0.2×	40 0.3×	57	780
Janusz Cianciara Poland	12	1.4k 1.5×	1.3k 1.5×	231 0.3×	73 0.3×	48 0.4×	33	1.5k
James Witek United States	17	606 0.7×	764 0.9×	495 0.7×	377 1.7×	56 0.5×	56	1.2k
Carey Hwang United States	20	250 0.3×	396 0.5×	802 1.1×	665 3.0×	188 1.5×	49	1.2k
Romina Salpini Italy	19	427 0.5×	475 0.6×	409 0.6×	194 0.9×	87 0.7×	62	902
Barbara McGovern United States	5	1.0k 1.1×	831 1.0×	385 0.5×	186 0.8×	79 0.6×	7	1.4k
Benedetta Massetto United States	23	1.9k 2.1×	1.9k 2.2×	391 0.5×	49 0.2×	82 0.7×	44	2.3k

Countries citing papers authored by Ross Martin

Since Specialization

Citations

This map shows the geographic impact of Ross Martin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ross Martin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ross Martin more than expected).

Fields of papers citing papers by Ross Martin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ross Martin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ross Martin. The network helps show where Ross Martin may publish in the future.

Co-authorship network of co-authors of Ross Martin

This figure shows the co-authorship network connecting the top 25 collaborators of Ross Martin. A scholar is included among the top collaborators of Ross Martin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ross Martin. Ross Martin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Han, Dong, Pui Yan Ho, Jiani Li, et al.. (2025). Remdesivir and Obeldesivir Retain Potent Antiviral Activity Against SARS-CoV-2 Omicron Variants. Viruses. 17(2). 168–168. 1 indexed citations

Andreatta, Kristen, Michelle L. D’Antoni, Silvia Chang, et al.. (2024). High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre‐existing HIV resistance and suboptimal adherence. Journal of Medical Virology. 96(10). e29899–e29899. 6 indexed citations

Selzer, Lisa, Laurie A. VanderVeen, Ross Martin, et al.. (2024). Susceptibility Screening of HIV-1 Viruses to Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, in People With HIV-1 Suppressed by Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 98(1). 64–71. 2 indexed citations

Li, Jiani, Ross Martin, Dong Han, et al.. (2024). SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participants. Antimicrobial Agents and Chemotherapy. 69(2). e0123824–e0123824. 2 indexed citations

Boopathy, Archana V., Bhawna Sharma, Silpa Suthram, et al.. (2023). Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys. npj Vaccines. 8(1). 175–175. 3 indexed citations

Buuren, Nicholas van, Ricardo Ramírez, Cameron M. Soulette, et al.. (2022). Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis B. JHEP Reports. 4(4). 100449–100449. 37 indexed citations

Pitts, Jared, Jiani Li, Jason K. Perry, et al.. (2022). Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants. Antimicrobial Agents and Chemotherapy. 66(6). e0022222–e0022222. 48 indexed citations

Liu, Yang, Silvia Chang, David Hsieh, et al.. (2021). Generation of an HBV core phenotyping assay for evaluating HBV capsid compounds. Journal of Virological Methods. 292. 114117–114117. 2 indexed citations

Martin, Ross, Jiani Li, Jason K. Perry, et al.. (2021). Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir. Antiviral Research. 188. 105033–105033. 31 indexed citations

10.

Lo, Michael K., César G. Albariño, Jason K. Perry, et al.. (2020). Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases. Proceedings of the National Academy of Sciences. 117(43). 26946–26954. 45 indexed citations

11.

Acosta, Rima, Madeleine Willkom, Kristen Andreatta, et al.. (2020). Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance. JAIDS Journal of Acquired Immune Deficiency Syndromes. 85(3). 363–371. 20 indexed citations

12.

Han, Bin, Ross Martin, Simin Xu, et al.. (2019). Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-naïve subjects. Antiviral Research. 170. 104574–104574. 16 indexed citations

13.

Wei, Lai, Masao Omata, Young‐Suk Lim, et al.. (2018). HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China. Antiviral Research. 158. 178–184. 15 indexed citations

14.

Sarrazin, Christoph, Curtis Cooper, Michael P. Manns, et al.. (2018). No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients. Journal of Hepatology. 69(6). 1221–1230. 41 indexed citations

15.

Zeuzem, Stefan, Masashi Mizokami, Stephen Pianko, et al.. (2017). NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. Journal of Hepatology. 66(5). 910–918. 149 indexed citations

16.

Ku, Karin S., Ramakrishna K. Chodavarapu, Ross Martin, et al.. (2016). Sequencing Analysis of NS3/4A, NS5A, and NS5B Genes from Patients Infected with Hepatitis C Virus Genotypes 5 and 6. Journal of Clinical Microbiology. 54(7). 1835–1841. 7 indexed citations

17.

Wyles, David, Hadas Dvory‐Sobol, Evguenia S. Svarovskaia, et al.. (2016). Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. Journal of Hepatology. 66(4). 703–710. 60 indexed citations

18.

Svarovskaia, Evguenia S., Edward Gane, Hadas Dvory‐Sobol, et al.. (2015). L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions. The Journal of Infectious Diseases. 213(8). 1240–1247. 73 indexed citations

19.

Rajyaguru, Sonal, Huiling Yang, Ross Martin, Michael D. Miller, & Hongmei Mo. (2013). Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates. Antiviral Research. 100(2). 328–336. 1 indexed citations

20.

Wong, Kelly A., Simin Xu, Ross Martin, Michael D. Miller, & Hongmei Mo. (2012). Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a. Virology. 429(1). 57–62. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact